Vallely, Jaxon J.
Hudson, Kathryn E.
Locke, Susan C.
Wolf, Steven P.
Samsa, Gregory P.
Abernethy, Amy P.
LeBlanc, Thomas W. http://orcid.org/0000-0002-0546-7895
Funding for this research was provided by:
Helsinn Healthcare, S.A.
Article History
Received: 26 June 2018
Accepted: 5 February 2019
First Online: 14 February 2019
Compliance with ethical standards
: This study was reviewed and approved by the Duke University School of Medicine’s institutional review board.
: Tom LeBlanc has full control of all primary data and agrees to allow the journal to review these data if requested, provided this is done in accordance with Duke University policies regarding data. He reports consulting fees/honoraria in the last 12 months from Amgen, Abbvie, Agios, AstraZeneca, Celgene, Helsinn, Heron, Medtronic, Otsuka, Pfizer, Seattle Genetics, and Flatiron Health, as well as research grants to Duke University from the American Cancer Society, AstraZeneca, the Cambia Health Foundation, and Seattle Genetics. Amy Abernethy is a full-time employee of Flatiron Health, a member of the Roche Group; she advises SignalPath Research, The One Health Company and Robin Care; she is on the Board of Directors for Aetnahealth; and she has consulting fees from Bristol Meyers Squibb and Genentech. The remaining authors have no disclosures to report.